ACIP Presentation Slides: February 24-25, 2021 Meeting

Note: These files are not yet 508

We will add links to presentations as they are available.

February 24, 2021

Welcome & Introductions

• Welcome and Introductions
  Dr. J Romero
  Dr. A Cohn

Rabies Vaccines

• Introduction [8 pages]
  Dr. S Frey
• Rabies pre-exposure prophylaxis: summary of background information [21 pages]
  Dr. A Rao
• Rabies pre-exposure prophylaxis: summary of Evidence to Recommendations [35 pages]
  Dr. A Rao
• Approach to rabies post-exposure prophylaxis [25 pages]
  Dr. A Rao
• Work group interpretations of data about rabies immune globulin and next steps for the WG [20 pages]
  Dr. A Rao
• Rabies Vaccines
  Dr. A Rao

Dengue Vaccine

• Introduction [8 pages]
  Dr. K Poehling
• Results of dengue test independent evaluation [25 pages]
  Dr. F Medina
• Workgroup interpretation [7 pages]
  Dr. G Paz-Bailey

Tick-borne Encephalitis (TBE) Vaccine

• Introduction [6 pages]
  Dr. K Poehling
• TBE epidemiology in TBE endemic areas [26 pages]
  Dr. S Hills
• TBE among US civilian travelers and laboratory workers [17 pages]
  Dr. E Staples
• TBE among military personnel and dependents [22 pages]
  Dr. B McClenathan
• Summary of risks of TBE for U.S. travelers and laboratory workers and next steps [11 pages]
  Dr. S Hills

Ebola Vaccine

• Introduction [10 pages]
  Dr. S Frey
• Background on state designated Ebola Treatment Centers (ETC) [23 pages]
  Dr. A Joyce
• Laboratory Response Network (LRN) facilities and survey results [22 pages]
  Dr. A Joyce
• Review of preliminary workgroup discussions [19 pages]
  Dr. C Cossaboom

Hepatitis Vaccine

• Introduction [5 pages]
  Dr. S Frey
  
• Background [25 pages]
  Dr. M Weng
• Economic analysis [36 pages]
  Dr. E Hall

February 25, 2021

Welcome & Introductions

• Welcome and Introductions
  Dr. J Romero
  Dr. A Cohn

Pneumococcal Vaccines

• Introduction [10 pages]
  Dr. K Poehling
• Current epidemiology of pneumoccocal disease and pneumococcal vaccine coverage in US adults [33 pages]
  Dr. R Gierke
• PCV20 Phase 2/3 study results in adults [16 pages]
  Dr. W Watson
• PCV15 Phase 2/3 study results in adults, including adults with underlying conditions [38 pages]
  Dr. U Buchwald
• Considerations for PCV15 and PCV 20 use in adults [43 pages]
  Dr. M Kobayashi

Zoster Vaccine

• Introduction [8 pages]
  Dr. G Lee
• Risk of Guillain-Barré syndrome (GBS) following recombinant zoster vaccine (RZV) [15 pages]
  Dr. R Forshee
• RZV risk-benefit analysis [21 pages]
  Dr. L Prosser
• Work group interpretation [7 pages]
  Dr. T Anderson
• Introduction of the Evidence to Recommendations Framework for use of RZV in immunocompromised adults [19 pages]
  Dr. T Anderson

Influenza Vaccines

• Introduction [5 pages]
  Dr. K Talbot
  
• Influenza surveillance update and work group considerations [26 pages]
  Dr. L Grohskopf

Cholera Vaccine

• Introduction [5 pages]
  Dr. P Sanchez
• Introduction to cholera and cholera vaccines [47 pages]
  Dr. J Collins
• Vaxchora safety and immunogenicity data [24 pages]
  Dr. J McCarty
• Work group plans [3 pages]
  Dr. J Collins

Orthopoxviruses Vaccines

• Introduction and use of Vaccinia virus vaccine in persons at risk for occupational exposure to orthopoxviruses: WG update [10 pages]
  Dr. B Bell
• Workgroup considerations [16 pages]
  Dr. B Peterson
• Updated policy questions and progress on systematic review [26 pages]
  Dr. A Rao